Search Videos and More
News
Dana-Farber Cancer Institute Raises More Than $2 Billion in Record-Breaking Fundraising Campaign to Defy Cancer
Dana-Farber Cancer Institute today announced the completion of one of the largest fundraising campaigns focused entirely on cancer, raising a record $2.5 billion.
News
Patient, Testing Positive for Cancer on Early-Detection Test, Finds Guidance at Dana-Farber Clinic
Scott Menta describes himself as someone who “likes to stay on top of my health.” So, when he read about a new test that screens for cancer based on tumor cell DNA within the blood, he sprang for the cost of two tests — one for him and one for his wife.
News
Dana-Farber Cancer Institute Leads the Launch of IGNITE Consortium to Eradicate Health Inequities in Pediatric Cancer Care
In a bold step toward addressing the stark disparities in pediatric cancer care, Dana-Farber Cancer Institute is taking the lead in launching IGNITE—the first national, pediatric hematology-oncology health equity research consortium.
Document
Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-Low and HER2-Ultralow Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of trastuzumab deruxtecan (T-DXd) for patients with metastatic, HER2-low and HER2-ultralow breast cancer.
News
Prostate Cancer Vaccines: What’s the Latest?
Like all vaccines, prostate cancer vaccines work by stimulating the body’s immune system. Unlike vaccines for the flu, COVID-19 and other infections, which protect against disease, prostate cancer vaccines are a form of treatment.?
News
Researchers Uncover Key Actor in Spread of Breast Cancer to the Brain
When breast cancer metastasizes, it often heads for the brain, where it can be exceptionally difficult to root out. The key to preventing the spread of the cancer, or thwarting it if it does reach the brain, is to understand the mechanism that turns stationary tumor cells into nomadic intruders.
News
Expanding Possibilities - Researchers Dive Deep to Identify Exceptional Responders
In 2020, data from a clinical trial of patients with metastatic HER2-positive breast cancer caught the attention of Dana-Farber breast oncologist Heather Parsons, MD, MPH. She noticed what she describes as a "long tail."
News
Dana-Farber Research News 9.15.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 16 through August 31.
News
High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer
SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial of vitamin D combined with standard chemotherapy plus bevacizumab in patients with previously untreated metastatic colorectal cancer.
News
Breast Cancer Research: New Studies Show How Post-Treatment Lifestyle Choices Shape Long-Term Outcomes After Diagnosis
Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer.
News
Long-term Metastatic Melanoma Survival Dramatically Improves on Immunotherapy
Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Dana-Farber Cancer Center and Weill Cornell Medicine investigators and their colleagues.
News
Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor – Results of the Phase 3 TiNivo-2 Study